Magnus Petersson
BioPharmaceuticals R&D
Goeteborg, O, Sweden
Goeteborg, O, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction.
Journal: JACC. Heart failure
Published: January 28, 2025
Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease.
Journal: European heart journal
Published: May 22, 2024
Sex Differences in Heart Failure With Improved Ejection Fraction: The DELIVER Trial.
Journal: JACC. Heart failure
Published: March 18, 2024
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial.
Journal: European journal of heart failure
Published: February 07, 2024
Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials.
Journal: NEJM evidence
Published: February 06, 2024
Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVER.
Journal: European journal of heart failure
Published: February 02, 2024
Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVER.
Journal: European journal of heart failure
Published: December 07, 2023
Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial.
Journal: Circulation
Published: October 13, 2023
Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function.
Journal: Journal of the American College of Cardiology
Published: August 07, 2023
Last Updated: 09/26/2026